ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elecoglipron

Also written as “Elecoglipron”, “AZD5004” and “ECC5004”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Heart Failure · Renal Insufficiency, Chronic · Renal Insufficiency, led by 2 companies.

Drug pageElecoglipron: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 18, 202626 company-led studies, 11 open or runningLicense: Eccogene → AstraZeneca, Nov 2023Next primary completion: Nov 18, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only2211 open or runningphase 3since Jun 18, 2026Aug 13, 2024Nov 18, 2026phase 1 · NCT07723833
Eccogene40 open or runningphase 1since Dec 8, 2022Dec 8, 2022none ahead
  • Named in AstraZeneca’s own pipeline as elecoglipron, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Parexel and Quotient Sciences.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseAstraZeneca licensed it from Eccogene, for everywhere outside China, where the two develop and sell it together.Announced Nov 9, 2023 · Source: AstraZeneca, Nov 9, 2023

History and studies of Eccogene only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 8, 2022First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT05654831 · 69 enrolled · United States
  2. Nov 9, 2023AstraZeneca licensed it from EccogeneLicenseEverywhere outside China, where the two develop and sell it together · announced · AstraZeneca
  3. Feb 13, 20242 phase 1 studies in Diabetes Mellitus, Type 2NCT06268145, NCT06293742
  4. Feb 13, 2025Named elecoglipronINNProposed as its International Nonproprietary Name in WHO's List 132 · before, AZD5004, ECC5004
  5. May 16, 2025Phase 1 study in ObesityNCT06988553 · 45 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Eccogene leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06988553Obesity · China1CompletedNov 28, 202545
NCT06293742Diabetes Mellitus, Type 2 · United States1CompletedApr 15, 202448
NCT06268145Diabetes Mellitus, Type 2 · United States1CompletedMar 29, 202414
NCT05654831Diabetes Mellitus, Type 2 · United States1CompletedNov 1, 202369

How it is read

Names in the registry

  • “Elecoglipron”, 10 entries
  • “AZD5004”, 10 entries
  • “ECC5004”, 3 entries
  • “Elecoglipron Reference Formulation Dose A”, 1 entry
  • “Elecoglipron Reference Formulation Dose B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.